以前尚未报道过新西兰系统性硬化症患者的自身抗体谱。这项研究的目的是评估怀卡托医院系统性硬化症临床队列患者的自身抗体谱。EUROLINE(IgG)系统性硬化症面板测试试剂盒(用于测试Scl-70,CENP-A,CENP-B,RP11,RP155,Fib,NOR90,Th/To,PM100,PM75,Ku,选择PDGFR和Ro-52)用于本研究的目的。所有参加怀卡托医院系统性硬化症诊所的患者均应邀参加。这些患者按系统性硬化症亚型进行分类[1]。结果与以前发表的数据进行了比较,包括EUSTAR数据库。招募了60名患者(56名女性),年龄中位数为61岁(范围29-81岁)。41人患有局限性皮肤系统性硬化症(lcSSc)。在这些lcSSc患者中,31(75.6%)的CENP-A和CENP-B(抗着丝粒)抗体阳性,Ro-52抗体为12(29.3%),对于RP11和RP155为5(12.2%),对于Scl-70为4(9.8%),对于抗Fib和Th/To抗体为1(2.4%)。15例患者患有弥漫性皮肤系统性硬化症(dcSSc),其中7例(47.6%)RP11和RP155阳性,4例(26.7%)Scl-70阳性。三名dcSSc患者没有这两种主要抗体中的任何一种,但是在这15名dcSSc患者中,4例(26.7%)Ro-52阳性,2例(13.3%)抗Ku阳性,抗Fib和NOR90各1(6.7%)。四名患者患有重叠综合征(OLS),1具有CENP-A和CENP-B抗体,1具有Ro-52自身抗体1具有抗Ku抗体。三名患者没有自身抗体。这是第一个研究新西兰SSc患者的自身抗体谱的研究。与EUSTAR数据库相比,我们小组证明了针对着丝粒和RNA聚合酶III的抗体的患病率更高,这表明抗体的患病率可能在地理上有所不同。
The autoantibody profiles in New Zealand systemic sclerosis patients have not previously been reported. The aim of this
study was to evaluate the autoantibody profiles of patients in the Waikato Hospital Systemic Sclerosis Clinic cohort. The EUROLINE (IgG) Systemic Sclerosis panel test kit (which tests for Scl-70, CENP-A, CENP-B, RP11, RP155, Fib, NOR90, Th/To, PM100, PM75, Ku, PDGFR and Ro-52) was selected for the purpose of this
study. All patients attending the Waikato Hospital Systemic Sclerosis clinic were invited to participate. These patients were categorised by systemic sclerosis subtypes [1]. Results were compared with previously published data, including the EUSTAR database. Sixty patients (56 female) were recruited, with a median age of 61 years (range 29-81 years). Forty-one had limited cutaneous systemic sclerosis (lcSSc). Of these lcSSc patients, 31 (75.6%) were positive for CENP-A and CENP-B (anti-centromere) antibodies, 12 (29.3%) for Ro-52 antibodies, 5 (12.2%) for RP11 and RP155, 4 (9.8%) for Scl-70 and 1 (2.4%) each for anti-Fib and Th/To antibodies. Fifteen patients had diffuse cutaneous systemic sclerosis (dcSSc), of which 7 patients (47.6%) were positive for RP11 and RP155, 4 (26.7%) for Scl-70. Three dcSSc patients did not have either of these two major antibodies, but of these 15 dcSSc patients, 4 patients (26.7%) were positive also for Ro-52, 2 (13.3%) for anti-Ku, and 1 (6.7%) each for anti-Fib and NOR90. Four patients had overlap syndrome (OLS), 1 had CENP-A and CENP-B antibodies, 1 had Ro-52 autoantibodies 1 had anti-Ku antibodies. Three patients had no autoantibodies. This is the first
study to look at the autoantibody profile of SSc patients in New Zealand. A higher prevalence of antibodies against centromere and RNA polymerase III was demonstrated in our group compared with the EUSTAR database suggesting that antibody prevalence may vary geographically.